Patents Represented by Attorney Incyte Pharmaceuticals
  • Patent number: 6146624
    Abstract: The invention provides a human ubiquitin-conjugating enzyme (HUBI) and polynucleotides which identify and encode HUBI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HUBI.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: November 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Jennifer L. Hillman, Neil C. Corley
  • Patent number: 6057112
    Abstract: The present invention provides a human ubiquitin conjugation system protein (UCSP) and polynucleotides which encode UCSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of UCSP.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Preeti Lal, Purvi Shah
  • Patent number: 6015883
    Abstract: The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: January 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Olga Bandman, Lynn E. Murry
  • Patent number: 6010852
    Abstract: The present invention provides a human proton ATPase subunit (HPAS) and polynucleotides which encode HPAS. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HPAS.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: January 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6010879
    Abstract: The present invention provides a human mitochondrial chaperone protein (Hmt-GrpE) and polynucleotides which identify and encode Hmt-GrpE. The invention also provides expression vectors and host cells and a method for producing Hmt-GrpE. The invention also provides for antibodies or antagonists specifically binding Hmt-GrpE, and their use in the prevention and treatment of cancer. The invention also provides diagnostic assays. The invention also provides for the use of Hmt-GrpE in identifying antifungal and antiprotozoal therapeutics.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: January 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Patent number: 5994081
    Abstract: The invention provides human keratins (KERT) and polynucleotides which identify and encode KERT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of KERT.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: November 30, 1999
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Y. Tom Tang, Jennifer L. Hillman, Neil C. Corley, Mariah Baughn
  • Patent number: 5962263
    Abstract: The invention provides human membrane recycling proteins (HMRP) and polynucleotides which identify and encode HMRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HMRP.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: October 5, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
  • Patent number: 5958750
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP, and a method for making HHP with the host cells.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: September 28, 1999
    Assignee: Inctye Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5922595
    Abstract: The invention provides a human cyclic GMP phosphodiesterase (PDE9A) and polynucleotides which identify and encode PDE9A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE9A.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: July 13, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Douglas A. Fisher, Douglas H. Gooding, David Gray Streeter
  • Patent number: 5840544
    Abstract: The present invention provides a polynucleotide PTEC (prostate expressed chemokine) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: November 24, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Olga Bandman, Lynn E. Murry
  • Patent number: 5804376
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: September 8, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott Michael Braxton, Craig G. Wilde, Dinh Diep
  • Patent number: 5734038
    Abstract: The present invention provides polynucleotides which identify and encode a novel human Diazepam binding inhibitor/acyl-CoA binding protein (DBI/ACBP)-like protein (DBIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding DBIH. The invention also provides for the use of substantially purified DBIH for drug delivery as well as for the production of recombinant proteins for the treatment of diseases associated with the expression of DBIH. Additionally, the invention provides for the use of antisense molecules to DBIH in the treatment of diseases associated with the expression of DBIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding DBIH and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: March 31, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5700924
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 23, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Scott Michael Braxton, Dinh Diep, Susan G. Stuart
  • Patent number: 5686597
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 11, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer